BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 17496208)

  • 1. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
    Treiber A; Schneiter R; Häusler S; Stieger B
    Drug Metab Dispos; 2007 Aug; 35(8):1400-7. PubMed ID: 17496208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3.
    Gui C; Miao Y; Thompson L; Wahlgren B; Mock M; Stieger B; Hagenbuch B
    Eur J Pharmacol; 2008 Apr; 584(1):57-65. PubMed ID: 18321482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
    Noé J; Portmann R; Brun ME; Funk C
    Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The drug-drug interaction potential of rifampicin.
    Srinivas NR
    Clin Ther; 2008 Oct; 30(10):1932-3. PubMed ID: 19014849
    [No Abstract]   [Full Text] [Related]  

  • 5. Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae).
    Roth M; Araya JJ; Timmermann BN; Hagenbuch B
    J Pharmacol Exp Ther; 2011 Nov; 339(2):624-32. PubMed ID: 21846839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3.
    Bednarczyk D
    Anal Biochem; 2010 Oct; 405(1):50-8. PubMed ID: 20540932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug interaction between pitavastatin and various drugs via OATP1B1.
    Hirano M; Maeda K; Shitara Y; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1229-36. PubMed ID: 16595711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension.
    Taguchi M; Ichida F; Hirono K; Miyawaki T; Yoshimura N; Nakamura T; Akita C; Nakayama T; Saji T; Kato Y; Horiuchi I; Hashimoto Y
    Drug Metab Pharmacokinet; 2011 Jun; 26(3):280-7. PubMed ID: 21383523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat.
    Treiber A; Schneiter R; Delahaye S; Clozel M
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1121-9. PubMed ID: 14617681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.
    Gozalpour E; Greupink R; Wortelboer HM; Bilos A; Schreurs M; Russel FG; Koenderink JB
    Mol Pharm; 2014 Jun; 11(6):1844-55. PubMed ID: 24754247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver.
    Sato T; Yamaguchi H; Kogawa T; Abe T; Mano N
    J Pharm Pharm Sci; 2014; 17(4):475-84. PubMed ID: 25579430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
    Vavricka SR; Van Montfoort J; Ha HR; Meier PJ; Fattinger K
    Hepatology; 2002 Jul; 36(1):164-72. PubMed ID: 12085361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.
    Gertz M; Cartwright CM; Hobbs MJ; Kenworthy KE; Rowland M; Houston JB; Galetin A
    Pharm Res; 2013 Mar; 30(3):761-80. PubMed ID: 23179780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake.
    Shitara Y; Takeuchi K; Nagamatsu Y; Wada S; Sugiyama Y; Horie T
    Drug Metab Pharmacokinet; 2012; 27(4):368-78. PubMed ID: 22240838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors.
    Khurana V; Minocha M; Pal D; Mitra AK
    Drug Metabol Drug Interact; 2014; 29(4):249-59. PubMed ID: 24807167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
    Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
    Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes.
    Takahashi T; Uno Y; Yamazaki H; Kume T
    Biopharm Drug Dispos; 2019 Feb; 40(2):62-69. PubMed ID: 30652318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3.
    Martinez-Becerra P; Briz O; Romero MR; Macias RI; Perez MJ; Sancho-Mateo C; Lostao MP; Fernandez-Abalos JM; Marin JJ
    Mol Pharmacol; 2011 Mar; 79(3):596-607. PubMed ID: 21173039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
    Weiss J; Theile D; Spalwisz A; Burhenne J; Riedel KD; Haefeli WE
    Biochem Pharmacol; 2013 Jan; 85(2):265-73. PubMed ID: 23219525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Karlgren M; Vildhede A; Norinder U; Wisniewski JR; Kimoto E; Lai Y; Haglund U; Artursson P
    J Med Chem; 2012 May; 55(10):4740-63. PubMed ID: 22541068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.